Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TechMooseon Aug 12, 2021 9:49am
244 Views
Post# 33691024

Joseph Stauffer Saves the Day - But Where’s Wallace?

Joseph Stauffer Saves the Day - But Where’s Wallace?

Totally agree that Joseph Stauffer should be front and centre on these calls. He is far more reassuring than Dan.    Another smart addition would have been to have John Wallace there.  Even symbolically as a show of force having the chief scientific officer that would add value. On multiple occasions Dan refers to John Wallace in all of his presentations. But they never show him off. This is a major error from an investor relations perspective.  

Its all about scientific evidence and data at this point. No spin. I'll give Dan credit for some smart hires but when it comes to presenting he's got to make these guys more visible.

Now mulling over the idea of loading up on some additional shares. It's clear Antibe is not phased by this and they're playing a long game. 

<< Previous
Bullboard Posts
Next >>